Wolfgang Hiddemann Selected Research

Daunorubicin (Cerubidine)

1/2020	Loss of KDM6A confers drug resistance in acute myeloid leukemia.
12/2003	6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Hiddemann Research Topics

Disease

74	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2022 - 07/2002
42	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2022 - 01/2003
36	Neoplasms (Cancer) 09/2022 - 07/2002
24	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 09/2021 - 01/2003
23	Leukemia 09/2022 - 09/2002
20	Lymphoma (Lymphomas) 03/2022 - 01/2003
16	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/2021 - 01/2003
7	Disease Progression 05/2020 - 06/2003
7	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2018 - 06/2002
6	Acute Promyelocytic Leukemia 12/2021 - 01/2002
6	Hematologic Neoplasms (Hematological Malignancy) 10/2020 - 12/2004
5	Sarcoma (Soft Tissue Sarcoma) 04/2018 - 07/2002
4	Infections 10/2018 - 09/2002
4	Hyperthermia 04/2018 - 07/2002
4	Residual Neoplasm 01/2018 - 03/2006
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2016 - 08/2003
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/2009 - 12/2004
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2021 - 01/2019
3	Myeloid Leukemia (Leukemia, Myelocytic) 01/2020 - 01/2003
3	Pathologic Complete Response 01/2018 - 11/2004
2	Death (Near-Death Experience) 01/2017 - 11/2012
2	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/2016 - 05/2006
2	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2012 - 01/2005
2	Trisomy (Trisomies) 07/2011 - 09/2002
2	Genetic Translocation (Chromosomal Translocation) 12/2009 - 01/2009
2	Neutropenia 04/2009 - 09/2003
2	Chromosome Aberrations (Chromosome Abnormalities) 04/2007 - 09/2002
1	Thrombocytopenia (Thrombopenia) 12/2022

Drug/Important Bio-Agent (IBA)

32	Rituximab (Mabthera)FDA Link 03/2022 - 01/2003
17	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 01/2003
14	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 09/2003
13	obinutuzumabIBA 12/2022 - 02/2015
12	Monoclonal AntibodiesIBA 01/2020 - 04/2003
11	Cytarabine (Cytosar-U)FDA LinkGeneric 09/2021 - 12/2003
11	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 09/2003
10	Prednisone (Sone)FDA LinkGeneric 01/2019 - 12/2004
9	GalliumIBA 03/2022 - 10/2018
9	Proteins (Proteins, Gene)FDA Link 08/2013 - 08/2002
8	Mitoxantrone (Novantrone)FDA LinkGeneric 12/2018 - 01/2003
8	AntibodiesIBA 02/2015 - 06/2003
7	Biomarkers (Surrogate Marker)IBA 09/2022 - 08/2007
6	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 07/2003
6	fludarabineIBA 01/2018 - 06/2002
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2014 - 02/2003
5	Biological ProductsIBA 01/2022 - 10/2003
5	Bendamustine Hydrochloride FDA Link 12/2020 - 07/2007
5	Bortezomib (Velcade)FDA Link 01/2015 - 06/2003
5	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2014 - 11/2002
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2021 - 08/2003
4	Interferon-alpha (Interferon Alfa)IBA 09/2021 - 11/2004
4	Core Binding Factors (Core-Binding Factor)IBA 01/2020 - 04/2005
4	Etoposide (VP 16)FDA LinkGeneric 04/2018 - 04/2005
3	CytokinesIBA 01/2020 - 09/2003
3	RNA (Ribonucleic Acid)IBA 01/2019 - 08/2003
3	Ifosfamide FDA LinkGeneric 04/2018 - 01/2006
3	Phosphotransferases (Kinase)IBA 12/2014 - 02/2006
3	Proteasome InhibitorsIBA 06/2012 - 09/2008
3	Cyclin D1IBA 12/2009 - 01/2009
3	OligonucleotidesIBA 10/2009 - 08/2003
3	CCAAT-Enhancer-Binding Protein-alphaIBA 02/2006 - 07/2002
2	venetoclaxIBA 12/2022 - 12/2020
2	NucleotidesIBA 10/2021 - 01/2016
2	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2020 - 12/2003
2	Chlorambucil (Leukeran)FDA Link 01/2018 - 09/2006
2	Complement System Proteins (Complement)IBA 11/2016 - 01/2005
2	CreatinineIBA 08/2016 - 10/2012
2	Cisplatin (Platino)FDA LinkGeneric 08/2016 - 09/2002
2	fms-Like Tyrosine Kinase 3IBA 01/2016 - 05/2005
2	purineIBA 01/2015 - 09/2004
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2009 - 11/2006
2	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 06/2009 - 04/2003
2	pegfilgrastim (Neulasta)FDA Link 04/2009 - 09/2003
2	ProteomeIBA 12/2007 - 11/2006
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2006 - 07/2003
2	ibritumomab tiuxetan (Zevalin)FDA Link 08/2006 - 01/2005
2	NucleophosminIBA 06/2006 - 12/2005
2	Transcription Factors (Transcription Factor)IBA 08/2005 - 07/2003
2	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 04/2005 - 01/2002
2	CD40 Ligand (CD40L)IBA 09/2002 - 09/2002
1	EpitopesIBA 09/2022
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 09/2022
1	isocitric acid (isocitrate)IBA 01/2022
1	Long Noncoding RNAIBA 01/2022
1	Arsenic Trioxide (Trisenox)FDA Link 12/2021
1	RNA Splicing FactorsIBA 10/2020

Therapy/Procedure

69	Therapeutics 12/2022 - 06/2002
44	Drug Therapy (Chemotherapy) 03/2022 - 01/2003
13	Stem Cell Transplantation 09/2021 - 11/2004
6	Chemoradiotherapy 08/2016 - 11/2003
5	Immunotherapy 09/2022 - 07/2007
5	Transplantation 01/2016 - 01/2004
4	Salvage Therapy 01/2020 - 09/2006
4	Induction Chemotherapy 01/2018 - 01/2009
4	Palliative Care (Palliative Therapy) 01/2017 - 04/2005
3	Homologous Transplantation 02/2014 - 07/2005
3	Time-to-Treatment 12/2012 - 03/2005
2	Neoadjuvant Therapy 04/2018 - 07/2002
2	Critical Care (Surgical Intensive Care) 01/2017 - 01/2016
2	Hematopoietic Stem Cell Transplantation 01/2016 - 01/2013
2	Radioimmunotherapy 08/2006 - 07/2005